Your session is about to expire
← Back to Search
RAI + Immunotherapy for Thyroid Cancer
Study Summary
This trial is testing a new drug, durvalumab, to see if it can help treat thyroid cancer. Durvalumab blocks a protein that can be present on tumor and normal cells, which may help the immune system fight the cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had severe side effects from previous immunotherapy.I have had an autoimmune disease in the last 2 years.I have previously been treated with a PD1 or PD-L1 inhibitor.I have had pneumonitis before.My thyroid cancer is confirmed and is of a type that started in the follicular cells.My scans show at least one active cancer spot.I have an active case of tuberculosis.I have symptoms from cancer spread to my brain, spinal cord, or leptomeninges.I have not received a live vaccine within 30 days before joining the study or before getting durvalumab.I have no lasting side effects from cancer treatment worse than mild.I have or had inflammatory bowel disease.I cannot follow a low iodine diet or need medication high in iodide.Patients must have a condition that can be measured.My thyroid cancer has come back or spread.I am fully active or able to carry out light work.My organs and bone marrow are functioning well.I can provide samples from my thyroid cancer for testing.I haven't had 131I therapy in the last 6 months.I haven't had cancer treatments like chemotherapy or immunotherapy in the last 28 days.I am 18 years old or older.I have not had external beam radiation therapy in the last 4 weeks.I am willing and able to follow the study's treatment plan and attend all visits.You have had a severe allergic reaction to Thyrogen.I have seizures that are not controlled by medication.You have a history of a weak immune system from birth.You have received an organ from someone else in the past.I haven't taken immunosuppressive drugs in the last 28 days.You have had a bad reaction to durvalumab or any of its ingredients in the past.I do not have any unmanaged ongoing illnesses.I am not pregnant, breastfeeding, or if capable of having children, I am using effective birth control.
- Group 1: Radioiodine (RAI) in Combination with Durvalumab (Medi4736)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment open to recruitment at present?
"Unfortunately, this medical trial has reached its recruitment end date. It was first posted on July 10th 2017 and had a final update registered for January 25th 2022. If you are seeking other studies to join, there 230 active trials pertaining to thyroid diseases and 338 clinical tests recruiting patients using Durvalumab (Medi4736)."
For what clinical indications is Durvalumab (Medi4736) most commonly prescribed?
"Durvalumab (Medi4736) can assist in the management of advance directives, radioactive iodide uptake tests, and malignant neoplasms."
How many participants are engaging in this research project?
"This research is no longer actively seeking participants. It was originally posted on July 10th 2017 and the most recent edit took place on January 25th 2022. If you're looking for other options, there are currently 230 trials open to those with thyroid diseases and 338 studies recruiting new members that use Durvalumab (Medi4736)."
Are there any known precedents of research related to Durvalumab (Medi4736)?
"Presently, 338 clinical trials assessing Durvalumab (Medi4736) are underway. Of these, 51 are located in Phase 3 and 12917 sites across the country offer this treatment to patients. Cordoba, Texas is one of many locations running such studies."
Are there any offices in North America conducting this clinical investigation?
"At present, there are 7 trial sites recruiting participants for this medical study. The locales include Harrison, Commack, and Middletown alongside 4 other locations; it is advisable to select the closest site in order to reduce commuting requirements if you join the trial."
Share this study with friends
Copy Link
Messenger